Ocular Therapeutix, Inc.
OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$10.62
Price-7.41%
-$0.85
1Y
Price
Market Cap
$2.325b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-550.1%
EBITDA Margin-584.5%
Net Profit Margin-524.2%
Free Cash Flow Margin-550.1%
EBITDA Margin-584.5%
Net Profit Margin-524.2%
Free Cash Flow MarginRevenue
$52.054m
+0.5%
1y CAGR-3.1%
3y CAGR+1.1%
5y CAGREarnings
-$301.447m
-13.3%
1y CAGR-63.5%
3y CAGR-51.0%
5y CAGREPS
-$1.42
-
1y CAGR-12.0%
3y CAGR-10.3%
5y CAGRBook Value
$520.041m
$671.317m
Assets$151.276m
Liabilities$79.383m
DebtDebt to Assets
11.8%
-0.3x
Debt to EBITDAFree Cash Flow
-$255.100m
-17.6%
1y CAGR-51.8%
3y CAGR-44.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company